ABSTRACT
Precise control of diabetes mellitus, one of the most prevalent endocrine diseases, is important for prevention of serious vascular complications. Helicobacter pylori [H. pylori] is one of the most common chronic bacterial infections in the world and data reveals that diabetic patients with concomitant H. pylori infection require higher doses of insulin, despite which they have higher levels of HbAic than their uninfected counterparts. Our study was hence designed to assess the effect of H. pylori eradocatopmon hyperglycemia control in diabetic patients. Between January and June 2005, patients with type 2 diabetes mellitus and positive urea breath tests, were randomly allocated into two groups, the first treated for H. pylori infection [cases] and the second served as controls. HbAic and FBS were measured in all patients at initiation of study and three months later. The study included 19 cases and 22 controls. Mean decrease of HbAic and FBS in the two groups showed no significant differences. Study results indicate that treating H. pylori in patients with type 2 diabetes mellitus has no role in short-term control of the disease. In most studies numbers and types of evaluated cases have limitations, and results differ. More extensive studies, using long term randomized clinical trials-term are recommendated